Dermatology Company Announces Six Exclusive License Agreements

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company dedicated to pioneering treatments for severe skin conditions, has announced the signing of six exclusive license agreements. These agreements aim to commercialize two of its leading products, TWYNEO® and EPSOLAY®, across Europe and South Africa. $Sol-Gel Technologies(SLGL.US)$